less until none : a plan for a world without t1d
DESCRIPTION
Less Until None : A Plan for a World without T1D. JDRF’s Vision for the Future. LESS. UNTIL. NONE. 2. Mission: Less Until None. LESS. UNTIL. NONE. Burden. LESS. Invasive. LESS. Complexity. LESS. Danger. LESS UNTIL NONE. Delivery of Continuous Therapeutic Improvements. - PowerPoint PPT PresentationTRANSCRIPT
Less Until None:
A Planfor a World
without T1D
2
LESS UNTIL NONE
2
JDRF’s Vision for the Future
3
Mission: Less Until None
DangerLESS
ComplexityLESS
InvasiveLESS
BurdenLESS UNTIL NONE
LESS UNTIL NONE
4
Therapies CureDelivery of Continuous Therapeutic Improvements
Side-EffectsComplicationsPatient Burden
Glycemic ControlSafety
Normal Physiology Restored
Better Safety, Fewer Side-Effects, Less Exposure to Complications
5
$ $$$ $$$$$$
DiscoveryResearch
ClinicalDevelopment Regulatory Delivery
to Patients
ADVOCACY
RESEARCH
ADVOCACY
RESEARCH
ADVOCACY
RESEARCH
6
DiscoveryResearch
ClinicalDevelopment Regulatory Delivery
to Patients
ADVOCACY
RESEARCH
ADVOCACY
RESEARCH
ADVOCACY
RESEARCH
InvestmentInvestment$ $$$ $$$$$$
7
Near Term Medium Term Long Term
ComplicationsDiabetic Eye Disease
Insulin PumpsInfusion
Artificial PancreasLow Glucose Suspend
ComplicationsPredictive Diagnosis
Artificial PancreasTreat-to-Range
PreventionSecondary Prevention
Artificial PancreasTreat-to-Target
Artificial PancreasMultihormone
EncapsulationImplantable Islets
ControlGlucose Responsive Insulin
PreventionPrimary: Vaccine
ComplicationsComprehensive Prevention Therapy
Regeneration
This timeline is based on clinical delivery goals of identified therapies and will be updated as progress is achieved
8
Artificial PancreasAutomated technologies to help maintain better control of blood-glucose levels
Integrated smart technology to automate routine elements of insulin management
FDA released final guidance on pathway for commercialization of devices
9
Glucose Responsive Insulin (GRI)
Form of insulin that activated when blood-glucose levels start to rise
Simplifies life for and improves overall blood-glucose controls
JDRF competition underway to accelerate progress on GRI
10
EncapsulationEasily implantable Beta cells or islets surrounded by a protective shield/capsuleAble to sense glucose levels and produce insulin as neededHidden from the immune system to sustain normal functionEliminating the need for immunosuppressive drug therapy
11
Regeneration
Ability to create new insulin producing cells destroyed by autoimmune attack
Creating abundant supply of Beta cells through stem cells and regeneration
Immune therapy for suspected “triggers” including viruses
12
Secondary Prevention
Preserve beta cell function in these newly diagnosed individuals
Approaches include:Reducing inflammationBoosting beta cell survival Suppressing the autoimmune attack
13
Primary Prevention
Prevent the autoimmune attack on beta cells before it starts
Approaches include:Viral vaccinesBeta Cell Autoantigen Vaccines
14
Funding Scaleand Scope
IndustryInfluence
R&DExpertise
Government Advocacy
15
Funding Scaleand Scope
R&DExpertise
IndustryInfluence
Government Advocacy
16
More = LessT1DFunding $$$ Funding $$$Funding
FundingFunding
Funding Funding$$$LESS UNTIL NONEFunding
Funding
17
Thank you!